Cosmo NVCMOPF -3.22%82 Gross Margin % is 46.53% as of Dec. 2025, which is 43% below its 10-year median of 82.25. GuruFocus rates CMOPF with a GF Score™ of 82/100 and a GF Value™ of $54.86 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 938 Drug Manufacturers companies, Cosmo NV ranks better than 50.32% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Cosmo NV's Gross Profit for the
six
months ended in Dec. 2025 was $28.6 Mil. Cosmo NV's Revenue for the
six
months ended in Dec. 2025 was $61.4 Mil. Therefore, Cosmo NV's Gross Margin % for the quarter that ended in Dec. 2025 was 46.53%.
Warning Sign:
Cosmo NV gross margin has been in long-term decline. The average rate of decline per year is -6.8%.
The historical rank and industry rank for Cosmo NV's Gross Margin % or its related term are showing as below:
CMOPF'
s Gross Margin % Range Over the Past 10 Years
Min: 48.53 Med: 82.25 Max: 89.11
Current: 48.54
During the past 13 years, the highestGross Margin % of Cosmo NV was 89.11%. The lowest was 48.53%. And the median was 82.25%.
CMOPF's Gross Margin % is ranked better than 50.32% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs CMOPF: 48.54
Cosmo NV had a gross margin of 46.53% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cosmo NV was -6.80% per year.
Cosmo NV (OTCPK:CMOPF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cosmo NV had a gross margin of 46.53% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cosmo NV Gross Margin % Related Terms
Cosmo NV Gross Margin % Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cosmo NV (CMOPF) has a Gross Margin % of 46.53% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cosmo NV and its competitors. This is 43% below median its historical median of 82.25. Over the past decade, Cosmo NV's Gross Margin % has ranged from 48.53 to 89.11. According to the industry distribution chart, Cosmo NV ranks #466 out of 938 companies in the Drug Manufacturers industry, placing it in the top 49.7%.
Is Cosmo NV's Gross Margin % too high?
Cosmo NV's current Gross Margin % of 46.53% is 43% below median its 10-year median of 82.25. Over the past 10 years, this metric has ranged from a low of 48.53 to a high of 89.11. The Drug Manufacturers industry median Gross Margin % is 48.44. Cosmo NV's value of 46.53% is 3.9% below this industry median. Based on the distribution chart, Cosmo NV ranks #466 out of 938 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cosmo NV has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #466 out of 938 companies for Gross Margin %. This puts Cosmo NV in the upper half of its industry. The industry median Gross Margin % is 48.44. Cosmo NV's value of 46.53% is 3.9% below this benchmark. Historically, Cosmo NV's own Gross Margin % has ranged from 48.53 to 89.11 over the past decade. While the company's 10-year median is 82.25 vs. the industry median of 48.44, Cosmo NV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Gross Margin % of 46.53% is 3.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Gross Margin % is 46.53%, which is 43% below median its own 10-year median of 82.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.86, compared to a current price of $82.00 — trading 49.5% above its estimated fair value. The current Gross Margin % is 46.53%, which is 43% below median its 10-year median of 82.25 and 3.9% below the Drug Manufacturers industry median of 48.44. Cosmo NV's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Gross Margin % is 46.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $82.00 is trading 49.5% above its estimated GF Value™ of $54.86.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Gross Margin %: 46.53% (43% below median its 10-year median of 82.25)
GF Value™: $54.86 vs. price of $82.00 (49.5% above fair value)
Industry Position: 3.9% below the Drug Manufacturers median (#466 of 938)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
82GF Score
Get the complete analysis for CMOPF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
